Artificial intelligence integration is pushing the boundaries of biotechnology and diagnostics. Natera launched an AI foundational model platform blending genomic, clinical, and imaging data to advance therapeutic development and clinical decision-making. Tempus AI acquired Paige to accelerate oncology foundation model development through extensive pathology datasets. AI models enable novel antibiotic structure generation at MIT and reveal subtle changes in prostate cancer undetected by pathologists. Additionally, AI-enhanced wearables improve Parkinson’s medication adjustments, and innovative radiomics models refine cancer staging and treatment predictions.